Glaukos Corp Total Liabilities
Glaukos Corp total liabilities. Based on the latest financial reports, Glaukos Corp (GKOS) has total liabilities worth $222.40 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GKOS asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Glaukos Corp (2012–2025)
Total liabilities of Glaukos Corp from 2012 to 2025. This chart illustrates how Glaukos Corp's total liabilities have evolved over time, based on quarterly financial data.
Glaukos Corp Competitors by Total Liabilities
The table below lists competitors of Glaukos Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $71.86 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥2.74 Billion |
|
Jackson Financial Inc
NYSE:JXN
|
USA | $318.93 Billion |
|
Henry Schein Inc
NASDAQ:HSIC
|
USA | $6.48 Billion |
|
Canadian Utilities Limited
TO:CU
|
Canada | CA$17.82 Billion |
|
Ternium SA ADR
NYSE:TX
|
USA | $7.74 Billion |
|
Plaza S.A
SN:MALLPLAZA
|
Chile | CL$3.11 Trillion |
|
MOL NA A ADR REG.S 1/2
F:MOGG
|
Germany | €3.63 Trillion |
Liability Composition Analysis (2012–2025)
This chart breaks down Glaukos Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Glaukos Corp asset portfolio.
Liquidity & Leverage Metrics
Glaukos Corp Total Liabilities Ratios Explained
Glaukos Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Glaukos Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Glaukos Corp (2012–2025)
The table below shows the annual total liabilities of Glaukos Corp from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $237.33 Million | +14.20% |
| 2024-12-31 | $207.82 Million | -56.58% |
| 2023-12-31 | $478.65 Million | -12.04% |
| 2022-12-31 | $544.16 Million | +0.46% |
| 2021-12-31 | $541.68 Million | +60.23% |
| 2020-12-31 | $338.05 Million | +132.93% |
| 2019-12-31 | $145.13 Million | +338.32% |
| 2018-12-31 | $33.11 Million | +19.82% |
| 2017-12-31 | $27.63 Million | +61.63% |
| 2016-12-31 | $17.10 Million | -20.37% |
| 2015-12-31 | $21.47 Million | -88.51% |
| 2014-12-31 | $186.93 Million | +3.89% |
| 2013-12-31 | $179.92 Million | +1174.39% |
| 2012-12-31 | $14.12 Million | -- |
About Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for a… Read more